2-FMA
2-fluoro-N-methylamphetamine
Viewing r1.a1 — Oct 2, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
2-FMA (2-fluoromethamphetamine) is a synthetic stimulant of the phenethylamine class. It is a fluorinated structural analog of methamphetamine, distinguished by a cognitively focused, less euphoric profile than its parent. It releases dopamine and norepinephrine from nerve terminals into the synapse,[1][2] producing the focused wakefulness characteristic of amphetamine-type stimulants.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methamphetamine, other dopaminergic stimulants +1 moreamphetamine, methamphetamine, other dopaminergic stimulants, other fluorinated amphetamines show less
Ring-fluorinated amphetamine analogs emerged on gray markets in the early 2000s,[3] with forensic identification of the series first published in 2005.[4] 2-FMA became widely available as a research chemical around 2007–2010 and earned a reputation as the archetypal "functional" stimulant in online communities.[5] Today it remains unscheduled at the federal level in the United States but is explicitly controlled in Germany, Canada, and the United Kingdom.
Subjective effects include focus enhancement, wakefulness, motivation, appetite suppression, and increased heart rate. The experience is utilitarian — sustained, directed attention without the rush or compulsive redosing of more recreational stimulants.[6] Anxiety, jaw tension, insomnia, and cardiovascular strain are the characteristic unwanted effects.
Dependence potential is estimated as moderate by analogy to methamphetamine. Cardiovascular stress — elevated blood pressure, rapid heart rate, and vasoconstriction — is the primary physical danger, compounding with repeated use or high doses.[7][8] The evidence base is extremely thin — one rodent study, a single forensic metabolite case, and community self-reports.[9]
History[edit]
History
Discovery
No specific inventor has been identified for 2-FMA. It belongs to a family of ring-fluorinated amphetamine analogs that emerged from clandestine and commercial research chemical production rather than academic or pharmaceutical research. The first published analytical work on the group appeared in 2005, establishing forensic reference standards.[4]
Market appearance and forensic detection
2-FMA was circulating as a gray-market research chemical by approximately 2007, with broader online distribution from around 2010.[5] Italian forensic laboratories documented it among substances seized from internet purchases between 2013 and 2015.[10] A 2023 Japanese forensic case provided the only published data on how the compound is metabolized in humans.[3]
The name "2-FMA" follows standard research chemical nomenclature — the numeral marks the ring position of the fluorine atom. Among online communities, 2-FMA became the archetypal "functional stimulant": valued for sustained productivity rather than recreation, a framing that distinguishes it from its positional isomer 4-FMA, which has a more empathogenic, MDMA-adjacent reputation.
Chemistry[edit]
Chemistry
Structural class
2-FMA is a substituted amphetamine of the phenethylamine family. Its parent compound is methamphetamine, with a fluorine atom at the 2-position of the phenyl ring. Positional isomers 3-FMA and 4-FMA carry the same fluorine atom at the 3- and 4-positions respectively.
The position of the fluorine atom has pharmacological consequences. Para-fluorine substitution on amphetamine significantly boosts serotonin release potency relative to the unsubstituted parent[11] — an effect seen in 4-FMA but not established for the ortho (2-) position of 2-FMA. This difference likely explains 2-FMA's less empathogenic character compared to 4-FMA. Its molecular formula is C₁₀H₁₄FN (167.22 g/mol).
Pharmacology[edit]
Pharmacology
Mechanism of action
2-FMA's mechanism is inferred from structural analogy — no binding or release data exist for the compound directly. Amphetamine-type stimulants enter nerve terminals through dopamine and norepinephrine transporters, then reverse those transporters, pushing stored dopamine and norepinephrine out into the synapse.[1][2] The result is a surge of stimulating neurotransmitters throughout the brain.
In vivo pharmacology
The only animal study testing 2-FMA directly[6] found a revealing pattern: 2-FMA was comparatively weak at producing physical stimulation, but animals trained to recognize methamphetamine responded to 2-FMA as if it were the same drug. This dissociation — weak motor activation but a full methamphetamine-like internal signal — fits the community description of a drug that feels focused and functional rather than physically energizing.
Pharmacokinetics
No human pharmacokinetic data exist. A Japanese forensic case[3] identified three metabolic pathways: N-hydroxylation as the primary marker, conversion to 2-fluoroephedrine, and N-demethylation to 2-fluoroamphetamine — a profile that differs from methamphetamine's metabolism. The parent compound methamphetamine has a plasma half-life of approximately 11 hours,[12] suggesting 2-FMA may have a similar duration in the body.
Neuroscience[edit]
Neuroscience
Where it acts
No neuroimaging studies have been conducted with 2-FMA. By class inference, amphetamine-type stimulants boost dopamine signaling in two brain circuits: one running from the brainstem to the reward center, driving motivation, and another reaching the prefrontal cortex, supporting focus, working memory, and sustained attention.[2]
2-FMA's weak locomotor effect despite producing a full methamphetamine-like internal signal in animals[6] suggests it may act more strongly on the cortical circuits that handle thinking than on the subcortical circuits that drive movement — more prefrontal sharpening, less motor drive. This has not been directly tested.
Why it matters
Dopamine and norepinephrine improve prefrontal cognition only within a moderate range — too much impairs it as much as too little does. 2-FMA's productive cognitive window at common doses, followed by deterioration at high doses, fits this pattern. Chronic use depletes baseline dopamine and downregulates receptors, producing tolerance and the anhedonic flatness of withdrawal.
Whether 2-FMA preferentially engages cortical over subcortical dopamine circuits remains untested — it would explain the cognitive-over-motor profile. Its actual SERT activity is unknown. Whether chronic use produces the same dopaminergic depletion documented for methamphetamine has not been studied.
Subjective Effects[edit]
Subjective Effects
2-FMA produces a stimulant experience defined by cognitive clarity rather than euphoric intensity. Attention locks onto tasks, mental endurance extends, and motivation sharpens without the restlessness or compulsive redosing urge that marks more recreational amphetamines. The overall register is utilitarian — more like a sharp, clean focus than a rush.
Within the amphetamine class, 2-FMA sits closest to lisdexamfetamine in community comparisons: moderate duration, cognitively weighted, and low in acute reinforcement. It lacks the empathogenic warmth of its positional isomer 4-FMA, which has serotonergic qualities that give it an MDMA-adjacent character.[11]
Effect Grid
The core functional stimulant profile — sustained focus enhancement, motivation, clear-headed wakefulness, and productive task engagement. Thought acceleration and thought organization are prominent. Cognitive euphoria is present but moderate, described as less intense than d-amphetamine or methamphetamine. Community sources frequently compare this dose range to lisdexamfetamine (Vyvanse) in character.
Moderate appetite suppression, mild cardiovascular activation (elevated heart rate, mild vasoconstriction), and dry mouth. Pupil dilation may be noticeable. Restlessness can emerge toward the offset phase. Bruxism and sweating are generally absent or mild at this level.
This is the most frequently reported "functional" dose range. Sleep disruption extends well beyond subjective stimulation offset — wakefulness typically persists 8–10 hours even after core effects have declined. Plan accordingly.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Auditory enhancement · Sound sensitivity · Sleep-transition hallucinations · Visual acuity enhancement · Brightness alteration · Tinnitus · Object transformations
Brightness alteration · Tinnitus · Object transformations
Pupil dilation · Insomnia · Dry mouth · Physical fatigue · Excessive sweating · Restlessness · Dehydration sensation · Body high · Heart rate perception changes · Muscle tension · Nasal congestion · Abnormal heartbeat · Respiratory stimulation · Bodily lightness · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Nausea · Bruxism · Sexual arousal suppression · Sexual arousal enhancement · Headache · Sedation · Spontaneous body sensations · Trembling · Tactile euphoria · Increased urination · Breathing alteration · Dizziness · Vomiting
Physical fatigue · Excessive sweating · Restlessness · Dehydration sensation · Body high · Heart rate perception changes · Muscle tension · Nasal congestion · Respiratory stimulation · Bodily lightness · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Nausea · Bruxism · Sexual arousal suppression · Sexual arousal enhancement · Headache · Sedation · Spontaneous body sensations · Trembling · Tactile euphoria · Increased urination · Breathing alteration · Dizziness · Vomiting
Motivation enhancement · Immersion enhancement · Analysis enhancement · Thought organization · Information processing enhancement · Cognitive fatigue · Aesthetic enhancement · Cognitive flexibility · Conceptual thinking · Memory enhancement · Novelty enhancement · Creativity enhancement · Language enhancement · Motivation suppression · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Thought deceleration · Memory suppression · Cognitive dysphoria · Cognitive impairment · Multiple thought streams · Thought loops · Creativity suppression · Focus suppression · Thought disorganization · Delusions
Thought organization · Information processing enhancement · Cognitive fatigue · Aesthetic enhancement · Cognitive flexibility · Conceptual thinking · Memory enhancement · Novelty enhancement · Creativity enhancement · Language enhancement · Motivation suppression · Openness enhancement · Pattern recognition enhancement · Thought connectivity · Thought deceleration · Memory suppression · Cognitive dysphoria · Cognitive impairment · Multiple thought streams · Thought loops · Creativity suppression · Focus suppression · Thought disorganization
Emotional suppression · Anhedonia · Dysphoria · Emotional lability · Empathy enhancement · Mania
Emotional lability · Empathy enhancement
Craving · Flow state · Sociability enhancement · Self-control enhancement · Disinhibition · Social connection · Sociability suppression · Social disconnection · Depersonalization · Derealization
Disinhibition · Social connection · Sociability suppression · Social disconnection · Depersonalization · Derealization
Timeline
Gradual emergence of alertness and mild cognitive sharpening; minimal physical effects. A subtle increase in wakefulness becomes perceptible.
Progressive build of focus, motivation, and wakefulness. Mild appetite suppression begins. Task engagement increases noticeably.
Full functional stimulant profile — sustained focus enhancement, motivation, clear-headed wakefulness, moderate appetite suppression, mild cardiovascular activation. Thought organization and analysis enhancement are prominent.
Gradual decline in cognitive enhancement and motivation. Residual wakefulness persists well after subjective stimulation fades. Appetite begins returning; mild cognitive fatigue may emerge.
Wakefulness and mild restlessness persist after core effects have resolved. Potential for insomnia, mild irritability, and physical fatigue.
⚠ Avoid driving or operating machinery until a full sleep cycle has been completed.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · other dopaminergic stimulants
Toxicity
No lethal dose, systematic toxicity study, or published overdose case report exists for 2-FMA in any species. The fluorinated amphetamine class is associated with heart failure, cerebral hemorrhage, and death in emergency department reports.[6]
Heart and circulation
Cardiovascular toxicity is the primary physical danger. By analogy to methamphetamine, 2-FMA carries dose-dependent risk of elevated blood pressure, rapid heart rate, and vasoconstriction.[7][8] At high doses or with chronic exposure, these may escalate to dangerous heart rhythms, acute coronary events, or cerebral hemorrhage.
High doses also produce a sympathomimetic overdose picture: dilated pupils, tremor, agitation, overactive reflexes, seizures, and dangerously elevated body temperature.[13] inferred
Detection limitations
Standard amphetamine urine screens will not detect 2-FMA.[9] In an emergency room, this means 2-FMA toxicity can go unrecognized without specialized laboratory analysis. The recommended forensic markers are N-OH-2-FMA and 2-fluoroephedrine,[3] and standard methods cannot reliably distinguish 2-FMA from its positional isomers without advanced techniques.[4]
Psychological risks
No controlled data on psychological adverse effects exist. By class inference, anxiety, agitation, insomnia, and paranoia can emerge at higher doses or with repeated dosing in a single session. Community reports describe excessive stimulation and anxious thought patterns above 50 mg oral.[5]
High doses or sustained use can trigger paranoid delusions, auditory hallucinations, and agitation — well-documented with amphetamine-type stimulants.[14] 2-FMA's full substitution for methamphetamine in animal discrimination tests suggests this risk applies.[6] Sustained daily use is associated with cognitive impairment, emotional flattening, and depressive symptoms.
Tolerance and dependence
No 2-FMA-specific data exist. The following is class-level inference.
Tolerance develops as the brain adjusts its dopamine system — transporters upregulate, receptors downregulate, and baseline dopamine depletes. Community estimates suggest a tolerance half-life of approximately 5 days and full reset within 1.5 weeks.[5] Cross-tolerance occurs with other dopaminergic stimulants. safety citation needed
Dependence potential is estimated as moderate. Animal data show abuse potential comparable to methamphetamine based on discriminative stimulus substitution, though weaker locomotor effects may reduce acute reinforcement.[6] Self-administration studies have not been conducted. safety citation needed
Withdrawal after chronic use is expected to produce fatigue, excessive sleep, low mood, anhedonia, appetite enhancement, and cognitive difficulty.[15] Mirtazapine, naltrexone, and bupropion have shown preliminary benefit for methamphetamine withdrawal.[15]
Drug interactions
No 2-FMA-specific interaction data exist. All assessments are based on mechanism and class inference. safety citation needed
MAO inhibitors are the most dangerous combination. Combining 2-FMA with monoamine oxidase inhibitors risks severe blood pressure crisis and potentially fatal serotonin syndrome — the body can no longer break down surplus serotonin, flooding the nervous system.
Serotonergic agents such as tramadol carry dual danger: additive serotonergic effects and additive cardiovascular strain. This combination is classified as potentially lethal in harm-reduction databases.
Dissociatives such as PCP introduce unpredictable effects including dangerously elevated body temperature, lowered seizure threshold, and cardiovascular instability.
Other stimulants such as cocaine compound cardiovascular risk — additive blood pressure elevation, rapid heart rate, and vessel constriction.
CNS depressants (alcohol, GHB/GBL, opioids) may mask depressant effects during stimulant activity. As the stimulant wears off, respiratory depression can emerge.
Contraindications
No 2-FMA-specific contraindication data exist. The following are derived from the amphetamine class. inferred
Absolute:
- MAO inhibitor use: Risk of fatal blood pressure crisis and serotonin toxicity.
- Severe heart conditions: Including uncontrolled high blood pressure, coronary artery disease, recent heart attack, cerebrovascular disease, and aortic stenosis.
Relative:
- History of psychosis or schizophrenia: Amphetamine-type stimulants can trigger or worsen psychotic episodes.[14]
- Seizure disorders: Stimulants may lower seizure threshold.
- Overactive thyroid: Additive sympathomimetic effects.
- Glaucoma: pupil dilation from stimulant activity may trigger angle-closure crisis.
- Pregnancy and breastfeeding: Amphetamine-class compounds cross the placental barrier; no reproductive safety data exist for 2-FMA.
Harm Reduction[edit]
Forms & Identification
2-FMA circulates as an unregulated research chemical with no manufacturing standards. Batch purity varies unpredictably, and it cannot be visually distinguished from its positional isomers 3-FMA and 4-FMA — which have different pharmacological profiles (4-FMA is notably more serotonergic). Standard amphetamine immunoassay tests will not detect 2-FMA.[9]
Standard analytical methods cannot reliably distinguish 2-FMA from other fluoromethamphetamine isomers without advanced techniques.[4] Reagent testing provides partial identification but cannot confirm purity or rule out all adulterants. For a substance active at single-digit milligram doses, a milligram-precision scale is non-negotiable.
Guidelines
- Test every batch with reagent kits before use. Reagent results narrow the possibilities but do not confirm identity — consider sending a sample to a drug checking service if available.
- Weigh every dose on a milligram-precision scale (0.001g). Do not estimate by eye.
- Start low. First-time use or new batches warrant a threshold dose (5–10 mg oral) to assess individual response and batch potency.
- Oral is the lower-risk route. Insufflation produces faster onset and higher peak concentrations, increasing cardiovascular strain and the compulsive redosing urge.
- Avoid redosing. The long duration means a second dose stacks on the first. If the initial dose feels insufficient after 90 minutes, the session is unlikely to improve with more.
- Set a hard stop time. Decide before dosing when the session ends. Stimulant-driven focus makes it easy to keep working past the point of diminishing returns.
- Eat before dosing and have food accessible. Appetite suppression can last the full duration.
- Hydrate steadily but do not force excessive water intake.
Set & Setting
2-FMA is primarily used as a productivity tool. A familiar workspace suits the experience better than social or novel settings. Because the duration extends to 7–9 hours, afternoon dosing risks insomnia into the early morning hours.
Physical state matters. Elevated resting heart rate, high blood pressure, or recent stimulant use all increase cardiovascular risk. Adequate hydration and food before dosing help manage the appetite suppression and mild dehydration that accompany stimulant use.
Aftercare & integration. The stimulant comedown from 2-FMA is typically mild compared to more euphoric amphetamines but compounds with repeated use. Sleep, food, and rest are the priorities after a session.
Sleep recovery: Insomnia is common, especially with afternoon dosing. Avoid compensating with depressants or sedatives. Melatonin or a dark, quiet environment may help. Allow a full night of unrestricted sleep.
Nutrition: Appetite suppression may persist for several hours after effects fade. Calorie-dense, easy-to-eat foods help replenish what was missed during the session.
Psychological reset: Repeated stimulant use can create a pattern where productive days require a dose and rest days feel flat. Pay attention to whether the substance is becoming a condition for normal function rather than an occasional tool.
Recovery & Support
Stimulant dependence often develops gradually. 2-FMA's "functional" framing can mask escalating use because the substance is associated with productivity rather than intoxication. Warning signs include inability to work without dosing, dose escalation, continued use despite cardiovascular symptoms, and withdrawal-driven low mood.
Amphetamine-class withdrawal is not medically dangerous but can be psychologically difficult — fatigue, anhedonia, and cognitive fog may persist for days to weeks.[15] Professional support options include outpatient addiction counseling, cognitive behavioral therapy, and peer support groups such as SMART Recovery. Mirtazapine, naltrexone, and bupropion have shown preliminary benefit for methamphetamine withdrawal.[15]
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable but manageable effects include mild anxiety, jitteriness, and rapid heartbeat. Seek immediate medical help if any of the following occur:
- Chest pain or pressure
- Severe headache with sudden onset (possible blood pressure crisis)
- Seizure or loss of consciousness
- Body temperature hot to the touch through clothing
- Extreme confusion, paranoia, or aggression that cannot be redirected
- Breathing difficulty
Immediate steps:
- 1. Call emergency services if any of the above signs are present.
- 2. Move the person to a cool, quiet space. Remove excess clothing if overheating.
- 3. Do not restrain them unless they are in immediate physical danger.
- 4. Do not give other substances to "counteract" the stimulant.
- 5. Stay with the person until help arrives. Monitor breathing and consciousness.
What to tell the dispatcher:
State that the person has taken a stimulant (specify "fluorinated amphetamine structural analog" or "2-FMA" if known), the approximate amount, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
No specific reversal agent exists for amphetamine-type stimulant toxicity. Hospital management is supportive: cooling, sedation with benzodiazepines, and blood pressure control.
Legal Status[edit]
Legal Status
As of 2026, 2-FMA is explicitly controlled in several countries while remaining unscheduled at the federal level in the United States.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. Potentially prosecutable under the Federal Analogue Act (21 U.S.C. §813) if sold for human consumption with intent to produce effects substantially similar to a Schedule I or II substance[16] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled as an amphetamine analogue; maximum penalties include life imprisonment for supply[16] |
| Germany | Anlage I (BtMG) | Controlled since December 13, 2014; manufacture, possession, and import/export without license punishable by fine or up to 5 years imprisonment[17] |
| Canada | Schedule I (CDSA) | Controlled since 1996 as an analog of methamphetamine[16] |
| China | Controlled substance | Listed October 2015[16] |
| Ukraine | Narcotic | Controlled since July 2019[16] |
| Australia | Not specifically confirmed | No specific scheduling identified; analog provisions may applycitation needed |
Analog act considerations
In the United States, 2-FMA's structural relationship to methamphetamine places it within scope of the Federal Analogue Act, which treats substances substantially similar in structure and effect to Schedule I or II drugs as Schedule I — provided they are intended for human consumption. The full discriminative stimulus substitution for methamphetamine in rodent studies[6] could constitute pharmacological evidence of substantial similarity in a prosecution.
references
- [1] ^abSimmler LD, Liechti ME (2018) Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_113
- [2] ^abcLuethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
- [3]
- [4]
- [5]
- [6]